The Food and Drug Administration (FDA) approved Zepbound in December 2024 for treating obstructive sleep apnea (OSA). Medicare Part D may cover Zepbound, but only when a doctor prescribes it for OSA.

If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...

Food and drug companies have expressed optimism, but the new health secretary and his MAHA movement will likely make waves.

Eli Lily's GLP-1 competitor Mounjaro/Zepbound doesn't make the list ... Inflation Reduction Act is lowering prices for people on Medicare. HHS will continue negotiating in the best interest ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The situation is causing the FDA regulatory headaches and, more seriously, posing ...

Both Mounjaro and Zepbound have the same active ingredient ... GLP-1 drugs and expects improvements in 2025, particularly with Medicare and Medicaid. It is also seeing solid progress with the ...

The U.S. agency that oversees Medicare is taking out questions on enrollment application forms that ask people about their sexual orientation and gender identity. In response to President Trump ...

Health-insurance giant Humana is dropping a staggering 550,000 of its less profitable Medicare Advantage customers, or about 10% of the total, this year as it tries to restore its stock price and ...